A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
Public ClinicalTrials.gov record NCT02329327. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)
Study identification
- NCT ID
- NCT02329327
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 479 participants
Conditions and interventions
Conditions
Interventions
- Andexanet Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 9, 2015
- Primary completion
- Sep 23, 2020
- Completion
- Sep 23, 2020
- Last update posted
- Feb 15, 2022
2015 – 2020
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Study Site | Long Beach | California | — | — |
| Clinical Study Site | Los Angeles | California | — | — |
| Clinical Study Site | Orange | California | — | — |
| Clinical Study Site | Fort Lauderdale | Florida | — | — |
| Clinical Study Site | Jacksonville | Florida | — | — |
| Clinical Study Site | Sarasota | Florida | — | — |
| Clinical Study Site | Tampa | Florida | — | — |
| Clinical Study Site | Annapolis | Maryland | — | — |
| Clinical Study Site | Boston | Massachusetts | — | — |
| Clinical Study Site | Detroit | Michigan | — | — |
| Clinical Study Site | Royal Oak | Michigan | — | — |
| Clinical Study Site | Troy | Michigan | — | — |
| Clinical Study Site | St Louis | Missouri | — | — |
| Clinical Study Site | Rochester | New York | — | — |
| Clinical Study Site | Asheville | North Carolina | — | — |
| Clinical Study Site | Chapel Hill | North Carolina | — | — |
| Clinical Study Site | Raleigh | North Carolina | — | — |
| Clinical Study Site | Cincinnati | Ohio | — | — |
| Clinical Study Site | Cleveland | Ohio | — | — |
| Clinical Study Site | Pittsburgh | Pennsylvania | — | — |
| Clinical Study Site | Austin | Texas | — | — |
| Clinical Study Site | Fort Worth | Texas | — | — |
| Clinical Study Site | Huntington | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02329327, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 15, 2022 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02329327 live on ClinicalTrials.gov.